Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) on April 11, 2024, covering events occurring on April 5, 2024. The filing addresses significant changes in the Company's executive leadership structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a disclosure of personnel changes.
Material Changes
- Resignation of CFO: Melissa Epperly resigned as Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer, effective immediately on April 5, 2024.
- Interim Appointments:
- Cam Gallagher (President) was appointed interim Chief Financial Officer, Treasurer, and principal financial officer.
- Vincent Vultaggio (Vice President, Finance) was appointed interim principal accounting officer.
- Kyle Rasbach (Chief Business Officer) will oversee Investor Relations on an interim basis.
- Severance: Ms. Epperly is eligible for severance benefits under her employment agreement, subject to signing a release agreement.
Outlook, Risks, and Management Commentary
The Company is currently conducting a search for a permanent Chief Financial Officer. The filing notes that there are no undisclosed arrangements or understandings regarding the selection of the interim officers. No specific risks, contingencies, or unusual items related to financial operations were disclosed in this report.
Investor Verification Checklist
- Verify the status of the search for a permanent Chief Financial Officer.
- Review the terms of the Amended & Restated Employment Agreement (Exhibit 10.11 to the 2023 10-K) to understand potential severance costs.
- Monitor future filings for the appointment of a permanent CFO and any related compensation arrangements.
- Confirm that the interim leadership team has the necessary resources to manage financial reporting and investor relations during the transition.